Do Low- and Middle-Income Countries Learn from the Experience of High-Income Countries?

Predictors of long-term outcome of patients with schizophrenia in Africa: systematic review and meta-analysis

BACKGROUND

One of the most compelling areas of schizophrenia research involves the investigation of its longitudinal course and clinical outcomes. Longitudinal studies have provided profound insights into the trajectory of schizophrenia, elucidating its progression, clinical phenotype, functional impairments, treatment responsiveness, and key prognostic determinants. While contemporary therapeutic interventions have demonstrated promise in altering disease trajectory and enhancing recovery, schizophrenia remains characterized by heterogeneous outcomes, distinguishing it from other psychotic disorders. This review aims to assess the pooled prevalence of positive outcomes and identify key predictors on individuals with schizophrenia disorder across Africa.

METHODS

A comprehensive systematic search was conducted across multiple databases, including PubMed/MEDLINE, Scopus, African Journal Online, PsycINFO, EMBASE, Psychiatry Online, CINAHL, Science Direct, and the Cochrane Library. This review includes observational studies, comprising both cross-sectional and cohort designs, published between 1993 and 2024, that evaluate the prognosis and favorable clinical outcomes of schizophrenia in Africa. The literature search was performed between November 2, 2024, and December 20, 2024. A total of sixteen original research articles assessing the prevalence of favorable outcomes in individuals with schizophrenia met the inclusion criteria. Data extraction was conducted independently by two reviewers to ensure methodological rigor, and the review is registered with PROSPERO (ID: CRD42024613692).

RESULTS

The pooled prevalence of positive outcomes among individuals with schizophrenia disorder in Africa was estimated at 44.17% (95% CI: 32.27-56.08). Among a total of 2,263 individuals, the aggregated remission rate across 13 studies was 48.14%, while the pooled recovery rate was 42% among 474 individuals across 4 studies. Furthermore, significant predictors of positive outcomes included the presence of prominent positive symptoms (OR = 1.89, 95% CI: 1.24-2.89), prolonged antipsychotic use (OR = 2.15, 95% CI: 1.69-2.74), and good medication adherence (OR = 4.31, 95% CI: 2.17-8.56).

CONCLUSION

This review reveals that nearly half of individuals with schizophrenia in Africa achieve favorable outcomes, despite ongoing challenges. Key predictors-prominent positive symptoms, prolonged antipsychotic use, and good medication adherence-significantly influence prognosis. These findings underscore the need for early, personalized interventions and sustained treatment adherence. Given the heterogeneity of outcomes, region-specific strategies are essential to optimize care.

Combination of Two Long-Acting Antipsychotics in Schizophrenia Spectrum Disorders: A Systematic Review

BACKGROUND

Up to 34% of patients with schizophrenia are resistant to several treatment trials. Lack of continuous and adequate treatment is associated with relapse, rehospitalization, a lower effect of antipsychotic therapy, and higher risk of side effects. Long-acting injectables antipsychotics (LAI APs) enhance compliance and improve clinical outcomes and quality of life in patients with schizophrenia, and thus it may be advisable to administer two LAI APs at the same time in cases of treatment-resistant schizophrenia. The purpose of this review is to summarize the available literature regarding the combined use of two LAI APs in patients with schizophrenia or other psychotic spectrum disorders.

METHODS

An extensive literature search for relevant articles regarding any combination of two long-acting injectable antipsychotics has been performed from inception up to 9 February 2024, on PubMed, Scopus and APA PsycInfo, according to the PRISMA statement. Only studies reporting combination of two LAI APs and its clinical outcome in patients with schizophrenia and related disorders were selected.

RESULTS

After the selection process, nine case reports, four case series and two observational retrospective studies were included in the final analysis. All patients treated with dual LAI APs reported a good response, and no new or unexpected adverse effects due to the combination of two LAIs were reported. Different drug combinations were used, and the most frequent association resulted in aripiprazole monohydrate + paliperidone palmitate once monthly (32 times).

CONCLUSIONS

Our review highlights that the treatment regimen with two concurrent LAI APs is already widely used in clinical practice and is recognized as providing a promising, effective, and relatively safe therapeutic strategy for treating the schizophrenia spectrum disorders.

The relationship between human development and prevalence of deficit schizophrenia: Results from a systematic review and meta-analysis

This study examined the relationship between the prevalence of deficit schizophrenia (DS) and a country's Human Development Index (HDI). A systematic review and meta-analysis of the literature published in the last decade were conducted to acquire data on the worldwide prevalence of deficit syndrome in schizophrenia cohorts and examine the correlation between DS prevalence and the HDI of the countries in the review. Twenty-six studies meeting our eligibility criteria provided prevalence data on DS in 14 countries with both low-to-middle and high-incomes, ranging from 14.34%-to 61.57%. The pooled prevalence of DS was 32.19% (95% CI = 26.17 to 38.52). Statistical analysis yielded a correlation coefficient (r) of -0.518 (95% CI = -0.754 to -0.164; p = 0.007), indicating a moderate inverse correlation between DS prevalence and HDI. This relationship remained significant in partial correlation analysis after controlling for potential sources of bias in the DS estimates (r = -0.489, p = 0.013). Our results show that schizophrenia cohorts from low-to-middle-income countries are more prone to primary and enduring negative symptoms, and contribute to the emerging evidence questioning the axiom that schizophrenia in the developing world has a better course than in high-income countries.

Management of schizophrenia in women during the perinatal period: a synthesis of international recommendations

INTRODUCTION

The perinatal period in schizophrenia is associated with high risk of psychotic relapse and pregnancy/child outcomes. The extent to which antipsychotics may potentially affect the fetus or the child development is unclear and debated. Even though guidelines have been developed, there is a lack of consensual recommendations regarding the optimal strategy to manage schizophrenia during the perinatal period.

AREAS COVERED

This systematic review describes the current state of evidence with respect to the impact of recommended interventions for schizophrenia during the perinatal period, including childbearing age, pregnancy and post-partum. It compares recent international treatment guidelines for this specific group of women. Last, this review presents a set of major points to be discussed with patients and relatives for shared-decision making and a summary of key recommendations from the international guidelines.

EXPERT OPINION

Although treatment guidelines may be of significant help, discrepancies exist across them regarding the management of antipsychotics for schizophrenia women during the perinatal period. Shared decision-making and advance directives represent useful patient-centered approaches during this specific period. Further cohort-based evidence is needed to better identify maternal and fetal risks associated to antipsychotic treatment exposure.

A 6-week, multicenter, double-blind, double-dummy, chlorpromazine-controlled non-inferiorityrandomized phase iiitrial to evaluate the efficacy and safety of quetiapine fumarate (SEROQUEL) extended-release (XR) in the treatment of patients with schizophrenia and acute episodes

This study aimed to evaluate the efficacy and safety of quetiapine fumarate extended-release (XR) in the treatment of Chinese patients with acute schizophrenia. Multicenter, double-blind, double-dummy, active-controlled non-inferiority randomized study in Chinese patients (n = 388) with schizophrenia randomly assigned to quetiapine XR or chlorpromazine for 6 weeks. Primary outcome was the change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at the end of treatment. Safety objectives included adverse event (AE) monitoring, laboratory test results, and electrocardiograms. Changes in PANSS total score were -33.4 for quetiapine XR and -35.9 for chlorpromazine (P > 0.05). Least squares mean changes were: positive subscale, -9.9 ± 0.53 and -11.1 ± 0.51; negative subscale, -5.9 ± 0.50 and -6.7 ± 0.48; general psychopathology subscale, -12.9 ± 0.74 and -13.9 ± 0.71; aggression and hostility cluster scores, -4.8 ± 0.33 and -5.4 ± 0.32; and depression cluster scores, -1.8 ± 0.18 and -1.7 ± 0.18, for quetiapine XR and chlorpromazine, respectively. For quetiapine XR, AEs were constipation, dizziness, insomnia, and agitation, and nine patients (4.6%) discontinued due to AEs. For chlorpromazine, AEs were extrapyramidal symptoms, constipation, insomnia, dizziness, and agitation, and 17 patients (8.9%) discontinued due to AEs; two patients reported serious AEs. Quetiapine XR monotherapy was not inferior to chlorpromazine for treating acute schizophrenia in Chinese patients and was well tolerated.